Jefferies Maintains a 'Buy' on Varian Medical (VAR); Still Struggling Domestically but VAR Remains A Safe Bet
VAR Hot Sheet
Rating Summary:10 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Jefferies maintains a 'Buy' on Varian Medical (NYSE: VAR) price target raised from $72 to $77.
Analyst, Raj Denhoy, said, "A mixed FQ1 with revenues $8mn light but EPS ahead by $0.04 on a GM rebound, favorable product mix, and lower share count. F12 guidance largely intact, although sequential outlook a touch light on oncology order deal slippage. Shares could take a breather, but continued strong global demand, positive product cycle, and potential kicker from Siemens (NYSE: SI) exiting the market remain reasons to own VAR."
(Jefferies lowers FY12 EPS estimate from $3.98 to $3.95, but raises FY13 from $4.40 to $4.56)
For an analyst ratings summary and ratings history on Varian Medical click here. For more ratings news on Varian Medical click here.
Shares of Varian Medical closed at $69.24 yesterday, with a 52 week range of $48.72-$72.19.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Raj Denhoy, said, "A mixed FQ1 with revenues $8mn light but EPS ahead by $0.04 on a GM rebound, favorable product mix, and lower share count. F12 guidance largely intact, although sequential outlook a touch light on oncology order deal slippage. Shares could take a breather, but continued strong global demand, positive product cycle, and potential kicker from Siemens (NYSE: SI) exiting the market remain reasons to own VAR."
(Jefferies lowers FY12 EPS estimate from $3.98 to $3.95, but raises FY13 from $4.40 to $4.56)
For an analyst ratings summary and ratings history on Varian Medical click here. For more ratings news on Varian Medical click here.
Shares of Varian Medical closed at $69.24 yesterday, with a 52 week range of $48.72-$72.19.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
- UBS Maintains a 'Buy' on Express Inc. (EXPR); A Misstep, But Still A Consistent Performer
- Barclays Raises Estimates on PetSmart (PETM); Expect Continued Momentum Despite Challenging Macro
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
